Trials / Completed
CompletedNCT02378961
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection
A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Non-Genotype 1 HCV Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 128 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) in adults with chronic non genotype 1 hepatitis C virus (HCV) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VOX | 100 mg tablet(s) administered orally once daily with food |
| DRUG | SOF/VEL | 400/100 mg FDC tablet administered orally once daily with food |
Timeline
- Start date
- 2015-02-16
- Primary completion
- 2015-09-21
- Completion
- 2016-01-26
- First posted
- 2015-03-04
- Last updated
- 2020-03-03
- Results posted
- 2017-09-15
Locations
34 sites across 3 countries: United States, New Zealand, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02378961. Inclusion in this directory is not an endorsement.